Results 221 to 230 of about 91,338 (344)

Autoinflammation in patients with leukocytic CBL loss of heterozygosity is caused by constitutive ERK-mediated monocyte activation. [PDF]

open access: yesJ Clin Invest
Bohlen J   +63 more
europepmc   +1 more source

Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53. [PDF]

open access: yesFront Oncol, 2022
Butz H   +5 more
europepmc   +1 more source

MAINTENANCE AND LOSS OF HETEROZYGOSITY IN A THELYTOKOUS LINEAGE OF HONEY BEES (APIS MELLIFERA CAPENSIS)

open access: yesEvolution; international journal of organic evolution, 2012
F. Goudie   +5 more
semanticscholar   +1 more source

Exosome as bioactive nanovesicle for diagnostic and therapeutic applications in periodontitis

open access: yesBMEMat, EarlyView.
This review introduces the mechanism that exosomes participate in the pathogenesis of periodontitis and their potential as biomarkers for early diagnosis and summarizes the application of cell‐ or plant‐derived exosomes or engineered exosomes in periodontitis or periodontal regeneration while proposing the perspective of translational application of ...
Yu Wang   +6 more
wiley   +1 more source

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition. [PDF]

open access: yesCancer Res
Fey SK   +16 more
europepmc   +1 more source

Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas

open access: bronze, 1995
Seung‐Hoon Lee   +6 more
openalex   +1 more source

Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV

open access: yesBioinform., 2011
J. Sathirapongsasuti   +7 more
semanticscholar   +1 more source

Mechanism and role of regulated cell death in tumor immunity and immunotherapy

open access: yesCancer Communications, EarlyView.
Abstract Cancer immune checkpoint inhibitors (ICIs) have brought breakthroughs, but only about one‐third of cancer patients benefit from ICIs. In recent years, targeting non‐apoptotic regulated cell death (RCD) subtypes, such as ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis, has emerged as a novel strategy in cancer therapy due to ...
Jingwen Hu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy